<DOC>
	<DOCNO>NCT03006081</DOCNO>
	<brief_summary>Retinal nonperfusion drive vision-threatening complication pathological neovascularization , lead neovascular glaucoma , vitreous hemorrhage , tractional retinal detachment macular edema diabetic retinopathy . Thus , decrease nonperfusion area aid anti-VEGF agent might useful way prevent deteriorate course diabetic retinopathy . The main purpose study determine efficacy intravitreal aflibercept injection improvement retinal nonperfusion identify associate factor patient nonproliferative diabetic retinopathy moderate retinal nonperfusion .</brief_summary>
	<brief_title>The Efficacy Intravitreal Aflibercept Injection Improvement Retinal Nonperfusion Diabetic Retinopathy</brief_title>
	<detailed_description>Retinal nonperfusion drive vision-threatening complication pathological neovascularization , lead neovascular glaucoma , vitreous hemorrhage , tractional retinal detachment macular edema various retinal vascular disease include diabetic retinopathy retinal vein occlusion . Silva et al reveal retinal nonperfusion area correlate highly diabetic retinopathy severity recent paper . It clarify retinal nonperfusion synonymous retinal ischemia , implies tissue hypoxia , useful surrogate . Retinal nonperfusion know associated production vascular endothelial factor ( VEGF ) . Recently , Campochiaro et al report neutralization VEGF use ranibizumab improve macular edema reverse worsen retinal nonperfusion patient retinal vein occlusion diabetic macular edema . The precise mechanism improve perfusion VEGF treat eye uncertain . The author suggest VEGF exacerbate retinal ischemia increase leukostasis , intravitreal anti-VEGF agent may break feedback loop , allow reperfusion occur . There might portion circulation close permanently , reversible closure modulate VEGF . The study Campochiaro et al , however , limited review retinal nonperfusion within template consist Early Treatment Diabetic Retinopathy subfields mainly confine posterior pole fundus . Wide-field retinal imaging imaging technique allow view almost 200° fundus single image . It well show wide-field scan allow detection peripheral pathology may miss 75 degree achieve montaging Early Treatment Diabetic Retinopathy Study 7-standard field . To investigator knowledge , previous study evaluate longitudinal change retinal nonperfusion aflibercept treatment large area retina take advantage 200° field view diabetic retinopathy . The main purpose study determine efficacy intravitreal aflibercept injection improvement retinal nonperfusion identify associate factor patient nonproliferative diabetic retinopathy moderate retinal nonperfusion .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>A subject must meet follow criterion eligible inclusion study : 1 . Adults ≥ 18 year type 1 2 diabetes mellitus 2 . Patients diagnose nonproliferative diabetic retinopathy retinal nonperfusion ( Ischemic index &gt; 20 % ) Severe nonproliferative diabetic retinopathy Early proliferative diabetic retinopathy 3 . Willing able comply clinic visit studyrelated procedure 4 . Provide sign informed consent form A subject meet follow criterion exclude study . 1 . Systemic exclusion criterion 1 . Renal failure require hemodialysis peritoneal dialysis within 6 month prior baseline anticipate need hemodialysis , peritoneal dialysis time study 2 . Acute cardiovascular event ( acute myocardiac infarction and/or cerebral infarction ) within 1 year Visit 1 3 . Blood HbA1c level great 12 % Visit 0 2 . Ocular exclusion criterion 1 . Diabetic macular edema involve center macula ( Defined area center subfield OCT , Heidelberg Spectralis : ≥305 woman ; ≥320 men ) study eye 2 . Presence rubeosis ( neovascularization iris angle ) study eye 3 . Any current history retinal disease affect visual acuity study eye 4 . Previous treatment panretinal photocoagulation 5 . Previous treatment antiVEGF study eye within 6 month Visit 1 6 . Previous treatment intraocular periocular corticosteroid study eye within 6 month Visit 1 7 . Previous history intraocular surgery cataract surgery study eye 8 . Cataract surgery within 3 month Visit 1 study eye 9 . Yttriumaluminiumgarnet ( YAG ) capsulotomy study eye within 1 month Visit 1 10 . Aphakia study eye 11 . Elevated intraocular pressure ( ≥ 22 mmHg ) spite use topical IOP lower agent Visit 1 diagnosis glaucoma ( Visual field defect correspond glaucomatous optic neuropathy ) study eye 12 . Presence visually significant cataract study eye 13 . BCVA score &lt; 34 letter fellow eye 14 . Hypersensitivity aflibercept 15 . Ocular periocular infection 16 . Active intraocular inflammation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Retinal nonperfusion</keyword>
	<keyword>Aflibercept</keyword>
</DOC>